Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial - Moskowitz, C H; Nademanee, A; Masszi, T (Lancet, 2015)
et al.